Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 07, 2023

BUY
$2.85 - $5.18 $37,181 - $67,578
13,046 Added 26.65%
61,994 $203,000
Q3 2022

Nov 01, 2022

BUY
$2.85 - $8.73 $2,639 - $8,083
926 Added 1.93%
48,948 $185,000
Q2 2022

Aug 04, 2022

BUY
$4.69 - $9.84 $144,447 - $303,062
30,799 Added 178.82%
48,022 $374,000
Q1 2022

May 09, 2022

BUY
$8.44 - $16.89 $9,216 - $18,443
1,092 Added 6.77%
17,223 $160,000
Q4 2021

Feb 07, 2022

SELL
$14.7 - $19.89 $83,157 - $112,517
-5,657 Reduced 25.96%
16,131 $272,000
Q3 2021

Nov 04, 2021

BUY
$11.99 - $17.9 $6,618 - $9,880
552 Added 2.6%
21,788 $390,000
Q2 2021

Aug 06, 2021

BUY
$12.89 - $16.58 $60,080 - $77,279
4,661 Added 28.12%
21,236 $330,000
Q1 2021

May 06, 2021

BUY
$14.0 - $20.72 $69,538 - $102,916
4,967 Added 42.79%
16,575 $238,000
Q4 2020

Feb 09, 2021

SELL
$12.67 - $26.23 $69,951 - $144,815
-5,521 Reduced 32.23%
11,608 $228,000
Q3 2020

Nov 10, 2020

SELL
$11.92 - $15.87 $333 - $444
-28 Reduced 0.16%
17,129 $222,000
Q2 2020

Aug 06, 2020

BUY
$7.53 - $14.93 $36,294 - $71,962
4,820 Added 39.07%
17,157 $250,000
Q1 2020

May 11, 2020

BUY
$5.69 - $17.78 $12,717 - $39,738
2,235 Added 22.12%
12,337 $105,000
Q4 2019

Feb 05, 2020

BUY
$10.89 - $16.79 $46,685 - $71,978
4,287 Added 73.72%
10,102 $162,000
Q3 2019

Nov 12, 2019

BUY
$12.03 - $19.94 $10,020 - $16,610
833 Added 16.72%
5,815 $82,000
Q2 2019

Aug 08, 2019

BUY
$19.05 - $41.04 $8,153 - $17,565
428 Added 9.4%
4,982 $100,000
Q1 2019

Apr 26, 2019

BUY
$28.4 - $41.74 $14,540 - $21,370
512 Added 12.67%
4,554 $181,000
Q4 2018

Feb 08, 2019

BUY
$30.9 - $42.97 $30,096 - $41,852
974 Added 31.75%
4,042 $115,000
Q3 2018

Nov 13, 2018

BUY
$35.05 - $43.5 $107,533 - $133,458
3,068 New
3,068 $127,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $728M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.